| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/04/2002 | WO2002051831A1 Oxybenzamides derivatives as factor xa inhibitors |
| 07/04/2002 | WO2002051821A1 Therapeutic compounds |
| 07/04/2002 | WO2002051814A1 Benzoylpyridazines |
| 07/04/2002 | WO2002051807A1 Compounds |
| 07/04/2002 | WO2002051806A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| 07/04/2002 | WO2002051805A1 Indole derivatives as ligands of thyroid receptors |
| 07/04/2002 | WO2002051799A1 Biphenyl derivatives |
| 07/04/2002 | WO2002051796A1 Amide derivatives |
| 07/04/2002 | WO2002051460A2 Bioactive materials for aneurysm repair |
| 07/04/2002 | WO2002051442A1 Concomitant drugs |
| 07/04/2002 | WO2002051439A2 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
| 07/04/2002 | WO2002051438A2 Use of repulsive guidance molecule (rgm) and its modulators |
| 07/04/2002 | WO2002051435A2 New therapeutic uses of smr1 peptides |
| 07/04/2002 | WO2002051434A2 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 07/04/2002 | WO2002051431A1 Therapeutic and/or preventive agents for diseases due to retinal ischemia |
| 07/04/2002 | WO2002051423A1 Angiogenesis inhibitors |
| 07/04/2002 | WO2002051420A2 Methods and formulations for the treatment of female sexual dysfunction |
| 07/04/2002 | WO2002051418A1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
| 07/04/2002 | WO2002051407A1 Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 07/04/2002 | WO2002051405A1 New clinical treatment |
| 07/04/2002 | WO2002051403A1 Compositions of stable t3 and methods of use thereof |
| 07/04/2002 | WO2002051398A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof |
| 07/04/2002 | WO2002051396A1 Pharmaceutical compositions containing cyclobutene derivatives |
| 07/04/2002 | WO2002051387A1 Thermoformable solid pharmaceutical composition for controlled release of ivabradine |
| 07/04/2002 | WO2002051383A2 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart |
| 07/04/2002 | WO2002036556A3 Acylaminoalkyl-substituted benzenesulfonamide derivatives |
| 07/04/2002 | WO2002033100A3 Regulation of human adenylate cyclase, type iv |
| 07/04/2002 | WO2002032373A3 Estrogen receptor modulators |
| 07/04/2002 | WO2002028347A3 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 07/04/2002 | WO2002026324A3 Tocol-based compositions containing amiodarone |
| 07/04/2002 | WO2002020609A3 Interleukin-11 for the treatment of stroke and neuropathies |
| 07/04/2002 | WO2002017898A3 Compositions and methods for inducing vasorelaxation |
| 07/04/2002 | WO2002008183A3 Potassium channel inhibitors |
| 07/04/2002 | WO2002003991A3 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 07/04/2002 | WO2002002624A3 B7-like molecules and uses thereof |
| 07/04/2002 | WO2001092492A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/04/2002 | WO2001092283A3 Cobalamin compounds useful as cardiovascular agents and as imaging agents |
| 07/04/2002 | WO2001090148A8 Neurotransmitter transporters |
| 07/04/2002 | WO2001089557A3 Methods for preventing strokes by inducing tolerance to e-selectin |
| 07/04/2002 | WO2001078779A3 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 07/04/2002 | WO2001078768A3 Targeted vaccine delivery systems |
| 07/04/2002 | WO2001077169A3 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 07/04/2002 | WO2001077097A3 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 07/04/2002 | WO2001070266A3 Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| 07/04/2002 | WO2001068855A3 Gtp-binding protein gamma-12 subunit |
| 07/04/2002 | WO2001046176A3 Non peptide tachykinin receptor antagonists |
| 07/04/2002 | WO2001041791A9 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 07/04/2002 | WO2001041535A9 Eplerenone crystalline form |
| 07/04/2002 | WO2001025441A3 Tumour-specific vector for gene therapy |
| 07/04/2002 | WO2001016096A3 Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia |
| 07/04/2002 | US20020087205 Transcutaneous photodynamic treatment of targeted cells |
| 07/04/2002 | US20020087007 Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid |
| 07/04/2002 | US20020087002 Naphthalenyl piperidines as renin inhibitors |
| 07/04/2002 | US20020086996 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates |
| 07/04/2002 | US20020086995 Recrystallizing mercaptoalkanoylamino lactam acid under basic conditions using an agent that minimizes amount of disulfides |
| 07/04/2002 | US20020086994 Deprotection processes |
| 07/04/2002 | US20020086972 Adaptor protein FRS2 and related products and methods |
| 07/04/2002 | US20020086904 Methods of treating affective disorders using derivatives of (-)- venlafaxine |
| 07/04/2002 | US20020086891 Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols |
| 07/04/2002 | US20020086888 Substantially free from amlodipine aspartate side products, by reacting amlodipine or an acid addition salt thereof with excess maleic acid under acidic environment |
| 07/04/2002 | US20020086882 Regulates immune and inflammatory responses by binding to alpha 4 integrin, also know as Very Late Antigen; antiinflammatory agent |
| 07/04/2002 | US20020086872 Anticoagulants; may be embedded in or physically linked to materials used in manufacture of devices used in blood collection, circulation, stents |
| 07/04/2002 | US20020086871 Pharmaceutical composition for the treatment of CNS and other disorders |
| 07/04/2002 | US20020086859 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 07/04/2002 | US20020086830 (HARC), and polynucleotides which encode it; agonists, antibodies, or antagonists specifically binding HARC, and their use in treating diseases associated with expression of HARC |
| 07/04/2002 | US20020086381 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 07/04/2002 | US20020086360 Polypeptide for use in treatment of congestive heart failure, ischaemic heart defects, arrhytmias, cardioiomyopathy and stroke |
| 07/04/2002 | US20020086297 Gene alteration in the gene for the Gbeta3-subunit of the human G protein |
| 07/04/2002 | US20020086282 Methods and compositions for detecting compounds that modulate inflammatory responses |
| 07/04/2002 | US20020086059 Dissolving solid material in dimethyl ether under a pressure and heating; reducing pressure on solution to precipitate the solid material as pulverous formulation and to expand dimethyl ether into a gas, separating |
| 07/04/2002 | US20020086051 For delivering drug directly to interior portions of the body of a mammalian organism, such as to the eye |
| 07/04/2002 | US20020086049 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 07/04/2002 | US20020086004 Especially wherein said angiogenic factor is an endothelial cell growth factor chosen from the FGF family of growth factors and the VEGF family of growth factors. |
| 07/04/2002 | US20020085615 Differential scanning calorimeter |
| 07/04/2002 | DE10064994A1 Sulfamidothienopyrimidine Sulfamidothienopyrimidine |
| 07/04/2002 | DE10063294A1 New N-(heterocyclyl-alkyl)-fused norbornylamine derivatives, are NHE3 inhibitors useful e.g. for treating respiratory disorders, renal failure, intestinal dysfunction, lipid metabolism disorders or proliferative diseases |
| 07/04/2002 | DE10059144A1 Modulation der Transkription pro-inflammatorischer Genprodukte Modulating the transcription of pro-inflammatory gene products |
| 07/04/2002 | DE10044649A1 Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine Substituted 4-phenyl-1- (1-phenylcyclohexyl) -1,2,3,6-tetrahydropyridines |
| 07/04/2002 | CA2441896A1 Quinuclidine carbamate derivatives and their use as m3 antagonists |
| 07/04/2002 | CA2436739A1 Combination agent |
| 07/04/2002 | CA2433861A1 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart |
| 07/04/2002 | CA2433520A1 Novel compounds and compositions as cathepsin inhibitors |
| 07/04/2002 | CA2433264A1 Agent for treating and/or preventing diseases due to retinal ischemia |
| 07/04/2002 | CA2433100A1 Indole derivatives as ligands of thyroid receptors |
| 07/04/2002 | CA2433090A1 Dipeptidyl peptidase iv inhibitor |
| 07/04/2002 | CA2433081A1 Bioactive materials for aneurysm repair |
| 07/04/2002 | CA2432896A1 Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 07/04/2002 | CA2432715A1 Novel atopic dermatitis-associated gene and proteins |
| 07/04/2002 | CA2432645A1 Thermoformable solid pharmaceutical composition for controlled release of ivabradine |
| 07/04/2002 | CA2432570A1 New clinical treatment |
| 07/04/2002 | CA2432536A1 Angiogenesis inhibitor |
| 07/04/2002 | CA2432523A1 Compositions of stable t3 and methods of use thereof |
| 07/04/2002 | CA2432008A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| 07/04/2002 | CA2431916A1 New therapeutic uses of smr1 peptides |
| 07/04/2002 | CA2431913A1 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 07/04/2002 | CA2431883A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof |
| 07/04/2002 | CA2430719A1 A method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| 07/03/2002 | EP1219638A2 G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1) |
| 07/03/2002 | EP1219622A2 Pharmaceutical compositions for CNS and other disorders |
| 07/03/2002 | EP1219609A1 Aromatic nitrogenous six-membered ring compounds |